Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monsenso ASOCSE:MONSO -18.03%29 5-Year RORE % is -29.48 as of Dec. 2025. GuruFocus rates OCSE:MONSO with a GF Score™ of 29/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 508 Healthcare Providers & Services companies, Monsenso AS ranks worse than 77.36% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Monsenso AS's 5-Year RORE % for the quarter that ended in Dec. 2025 was -29.48%.
The industry rank for Monsenso AS's 5-Year RORE % or its related term are showing as below:
OCSE:MONSO's 5-Year RORE % is ranked worse than 77.36% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 2.08
vs OCSE:MONSO: -29.48
Monsenso AS (OCSE:MONSO) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Monsenso AS 5-Year RORE % Related Terms
Monsenso AS 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Monsenso AS's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, TEM: 5-Year RORE % Comparison
For the Health Information Services subindustry, Monsenso AS's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS 5-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Monsenso AS's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 5-year before.
Monsenso AS (OCSE:MONSO) has a 5-Year RORE % of -29.48 as of Dec. 2025. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Monsenso AS and its competitors. According to the industry distribution chart, Monsenso AS ranks #393 out of 508 companies in the Healthcare Providers & Services industry, placing it in the top 77.4%.
Is Monsenso AS's 5-Year RORE % too high?
Monsenso AS's current 5-Year RORE % is -29.48. Based on the distribution chart, Monsenso AS ranks #393 out of 508 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Monsenso AS has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's 5-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #393 out of 508 companies for 5-Year RORE %. This places Monsenso AS in the lower half of its industry. The industry median 5-Year RORE % is 2.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Healthcare Providers & Services company?
The median 5-Year RORE % among Healthcare Providers & Services companies is 2.08, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Monsenso AS and its competitors. For the Healthcare Providers & Services industry, the median 5-Year RORE % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current 5-Year RORE % is -29.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.30 — trading 100% above its estimated fair value. The current 5-Year RORE % is -29.48. Monsenso AS's overall GF Score™ is 29/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current 5-Year RORE % is -29.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.30 is trading 100% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
5-Year RORE %: -29.48
GF Value™: kr0.15 vs. price of kr0.30 (100% above fair value)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
29GF Score
Get the complete analysis for OCSE:MONSO
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
